Compare TLIH & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | TLIH | NEUP |
|---|---|---|
| Founded | 1998 | 1996 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8M | 10.3M |
| IPO Year | 2025 | N/A |
| Metric | TLIH | NEUP |
|---|---|---|
| Price | $0.41 | $3.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | ★ 396.2K | 82.1K |
| Earning Date | 09-30-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $51,204,304.00 | $15,649,448.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.94 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.31 | $2.90 |
| 52 Week High | $7.00 | $21.40 |
| Indicator | TLIH | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 37.32 |
| Support Level | N/A | $3.79 |
| Resistance Level | N/A | $4.15 |
| Average True Range (ATR) | 0.00 | 0.25 |
| MACD | 0.00 | 0.11 |
| Stochastic Oscillator | 0.00 | 13.95 |
Ten-League International Holdings Ltd is a Singapore-based provider of turnkey project solutions. Its business consists of sales of heavy equipment and parts, heavy equipment rental and provision of engineering consultancy services to port, construction, civil engineering and underground foundation industries. It currently conducts its operations through its wholly-owned subsidiaries. The equipment it provides is organized into four categories based on their functions and application scenarios, namely, foundation equipment, hoist equipment, excavation equipment and port machinery. The company operates in Singapore and Other International Countries.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.